<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412019000500277</article-id>
<article-id pub-id-type="doi">10.24245/gom.v87i5.2680</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Correlación entre el índice de malignidad de Jacobs II y el reporte anatomopatológico en tumores de ovario]]></article-title>
<article-title xml:lang="en"><![CDATA[Correlation between risk malignancy index Jacobs II and anatomopathological result in ovary tumors]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Meléndez-González]]></surname>
<given-names><![CDATA[Claudia Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saldaña-Solórzano]]></surname>
<given-names><![CDATA[César Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machorro-García]]></surname>
<given-names><![CDATA[Erick Genaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Habib]]></surname>
<given-names><![CDATA[Roberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Monterrey  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Monterrey  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2019</year>
</pub-date>
<volume>87</volume>
<numero>5</numero>
<fpage>277</fpage>
<lpage>287</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412019000500277&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412019000500277&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412019000500277&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO: Determinar la correlación entre el cálculo del índice de riesgo de malignidad de Jacobs II y el reporte anatomopatológico de tumores de ovario.  MATERIALES Y MÉTODOS:  Estudio observacional, retrospectivo y prospectivo, analítico y transversal efectuado en pacientes con diagnóstico de tumoración ovárica con marcador tumoral de Ca 125 atendidas en el Hospital Christus Muguerza Conchita, Nuevo León, de 2016 a 2018. Se realizó el cálculo del índice de riesgo de malignidad de Jacobs II: IRM = U x M x Ca 125. Las pacientes se dividieron dos grupos según los reportes de histopatología (benignos y malignos). Las variables de tendencia central se compararon con t de Student ajustada a normalidad de dos colas (p &lt; 0.05). Para describir las diferencias entre los grupos los muestreos categóricos se compararon con la prueba de Fisher de 2 colas o distribución de c2 (p &lt; 0.05). Se estudió la muestra para observar factores de riesgo-beneficio (AUROC) y determinar el coeficiente de momios, riesgo relativo, sensibilidad, especificidad y creación del modelo de regresión logística de los indicadores de interés.  RESULTADOS: Se seleccionaron 323 pacientes con diagnóstico de tumoración ovárica y se encontró que las pacientes con un índice de malignidad de Jacobs II mayor de 155.22 (AUROC 0.95) tuvieron mayor probabilidad de tener una lesión maligna por patología, con sensibilidad de 88% y especificidad de 91%.  CONCLUSIÓN: Existe una correlación entre el índice de riesgo de malignidad de Jacobs II con el reporte anatomopatológico de tumores de ovario.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE: To determine the correlation between the risk of malignancy index Jacobs II and anatomopathological result in ovarian tumors.  MATERIALS AND METHODS: Observational, retrospective, prospective, analytical and transversal study of patients with a diagnosis of ovarian tumor with tumor marker of Ca 125 and the result of pathology admitted to the Christus Muguerza Conchita Hospital in Nuevo León during a 2-year period (2016-2018). Risk of malignancy index Jacobs II was calculated: IRM = U x M x Ca 125. Two groups were divided according to the results of histopathology (benign and malignant). For variables of central tendency, were compared with Student&amp;apos;s t-test adjusted to two-tailed normality (P &lt;0.05). For categorical sampling, compared with the 2-tailed Fisher&amp;apos;s test to describe the differences between the groups or distribution c2 (P &lt;0.05). The sample was studied to observe risk / benefit factors (AUROC) as well as determination of the odds ratio, relative risk, sensitivity, specificity and creation of the logistic regression model of the indicators of interest.  RESULTS: It was found that patients with a Jacobs II malignancy index higher than 155.22 (AUROC 0.95) were more likely to have a malignant lesion due to pathology with 88% sensitivity and 91% specificity.  CONCLUSION:  There is a correlation between the risk index for malignancy of Jacobs II and the anatomopathological result in ovarian tumors.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tumor de ovario]]></kwd>
<kwd lng="es"><![CDATA[marcador tumoral]]></kwd>
<kwd lng="es"><![CDATA[neoplasias ováricas]]></kwd>
<kwd lng="es"><![CDATA[biomarcadores, tumor]]></kwd>
<kwd lng="en"><![CDATA[Ovarian tumor]]></kwd>
<kwd lng="en"><![CDATA[Tumor marker]]></kwd>
<kwd lng="en"><![CDATA[Ovarian Neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Biomarkers, Tumor]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arteaga]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cáncer de ovario diagnóstico y tratamiento]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2010</year>
<volume>78</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>415-35</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>The American College of Obstetricians and Gynecologists</collab>
<article-title xml:lang=""><![CDATA[The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk]]></article-title>
<source><![CDATA[AGOC Committee Opinion]]></source>
<year>2017</year>
<volume>716</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>The American College of Obstetricians and Gynecologists</collab>
<article-title xml:lang=""><![CDATA[Management of Adnexal Masses]]></article-title>
<source><![CDATA[AGOC Practice Bulletin,]]></source>
<year>2015</year>
<volume>83</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novoa-Vargas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historia natural del cáncer de ovario]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2014</year>
<volume>82</volume>
<page-range>613-22</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Preisler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validación de criterios ecográficos IOTA (International Ovarian Tumor Analysis Group) para caracterizar masas anexiales y determinar riesgo de malignidad en un grupo de mujeres con sospecha de cáncer de ovario]]></article-title>
<source><![CDATA[Rev Hosp Clín Univ Chile]]></source>
<year>2017</year>
<volume>28</volume>
<page-range>44-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schorge]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Williams Ginecología]]></source>
<year>2008</year>
<edition>2</edition>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
<publisher-name><![CDATA[McGrawHill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Treviño]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Cantú]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exactitud diagnóstica del índice de riesgo de malignidad II en mujeres posmenopáusicas con tumor anexial]]></article-title>
<source><![CDATA[Cir Cir]]></source>
<year>2016</year>
<volume>84</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109-14</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tien]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initial evaluation and referral guidelines for management of pelvic-ovarian masses]]></article-title>
<source><![CDATA[J Obstet Gynaecol Can]]></source>
<year>2009</year>
<volume>31</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>668-73</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montalvo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abordaje diagnóstico y referencia del tumor pélvico con sospecha de malignidad]]></article-title>
<source><![CDATA[Catálogo maestro de guías de práctica clínica]]></source>
<year></year>
<page-range>511</page-range><publisher-name><![CDATA[IMSS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>The American College of Obstetricians and Gynecologists</collab>
<article-title xml:lang=""><![CDATA[The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk]]></article-title>
<source><![CDATA[AGOC Committee Opinion]]></source>
<year>2011</year>
<volume>716</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
